🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Oxford
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Oxford

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca20 AbbVie17 Hoffmann-La Roche16 Eli Lilly and Company15 Merck Sharp & Dohme LLC14
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
365 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
NCT05817942Ulcerative Colitis
Alfasigma S.p.A.
Observational
509
Belfast, Bury, Exeter, Glasgow, London, Norwich, Oxford, Southampton
2023-06-12
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
Leicester, Norwich, Oxford
2023-06-07
Active, closed
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05881408Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
148
London, Oxford, Newcastle upon Tyne
2023-05-31
Recruiting
Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data
NCT05845255Quality of Life, Epilepsy (treatment Refractory)
MJN Neuroserveis, S.L
Observational
130
Oxford
2023-05-01
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
Phase 3
880
Leeds, Cardiff, Birmingham, London, Oxford, Salford
2023-04-25
Active, closed
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
Scholar Rock, Inc.
Phase 3
238
Leeds, London, Oxford
2023-04-17
Active, closed
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
NCT07304843Primary Biliary Cholangitis (PBC)
Umecrine Cognition AB
Phase 1/2
84
Birmingham, Glasgow, London, Newcastle, Nottingham, Oxford, Portsmouth, Wolverhampton
2023-04-14
Active, closed
Thoraflex Hybrid and Relay Extension Post-Approval Study
NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm
Vascutek Ltd.
Observational
352
Bristol, Oxford, Southampton
2023-03-17
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Day One Biopharmaceuticals, Inc.
Phase 3
418
Birmingham, Leeds, Liverpool, Manchester, Newcastle upon Tyne, Oxford, Southampton, Belfast
2023-02-27
Recruiting
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
NCT05471856Solid Tumors
Boehringer Ingelheim
Phase 1
66
London, Oxford, Sutton
2023-02-24
Recruiting
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
Phase 3
160
Cardiff, Wakefield, London, Oxford, Salford
2023-02-14
Recruiting
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
NCT05822908Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Vico Therapeutics B. V.
Phase 1/2
68
London, Oxford
2023-02-14
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Birmingham, Cambridge, Leeds, London, Oxford, Southampton
2023-02-03
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
Novartis Pharmaceuticals
Phase 3
152
London, Oxford
2023-02-02
Active, closed
A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
NCT05405361Multifocal Motor Neuropathy (MMN)
argenx
Phase 2
51
Glasgow, Oxford
2023-01-18
Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229Gastric Cancer
AstraZeneca
Phase 2
163
Edinburgh, Leeds, London, Oxford
2023-01-16
Active, closed
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407Systemic Lupus Erythematosus
Bristol-Myers Squibb
Phase 3
513
London, Central Middlesbrough, Oxford
2023-01-12
Active, closed
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241IgG4 Related Disease
Zenas BioPharma (USA), LLC
Phase 3
194
Oxford
2023-01-09
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical
Not applicable
300
London, Newcastle upon Tyne, Oxford
2023-01-06
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Oxford, Edinburgh
2023-01-05
By invitation
A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
NCT05768386Hemophilia A
BioMarin Pharmaceutical
Observational
172
Cambridge, Glasgow, London, Oxford, Southampton
2023-01-01
Active, closed
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526Alzheimer Disease
AriBio Co., Ltd.
Phase 3
1,535
Cambridge, Cornwell, Exeter, London, Motherwell, Oxford, Southampton
2022-12-23
Recruiting
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
NCT03994471End Stage Renal Disease
Iperboreal Pharma Srl
Phase 3
170
Birmingham, Bradford, Brighton, Canterbury, London, Oxford, Sheffield, Stoke-on-Trent
2022-12-14
Active, closed
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
Immunophotonics, Inc.
Phase 1/2
42
London, Oxford
2022-11-29
Active, closed
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3
260
Liverpool, London, Oxford, Sheffield
2022-11-21
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
Pfizer
Phase 3
1,116
Leicester, Edinburgh, Oxford, Stoke-on-Trent, Cardiff, Glasgow
2022-11-10
Active, closed
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
NCT05490446Myelodysplastic Syndromes
Agios Pharmaceuticals, Inc.
Phase 2
87
Aberdeen, Edinburgh, London, Oxford
2022-11-07
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102Advanced Solid Tumors
Bayer
Phase 1
284
London, Oxford, Sutton, Newcastle upon Tyne
2022-11-04
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05169515Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1
121
Glasgow, London, Nottingham, Oxford
2022-10-26
Active, closed
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
NCT05387525Keratosis, Actinic
Almirall, S.A.
Phase 4
447
London, Oxford, Poole, Weston-super-Mare
2022-10-24
Recruiting
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2
260
Manchester, Leicester, Liverpool, Oxford, London
2022-10-18
Active, closed
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05371093Relapsed/Refractory Follicular Lymphoma
Kite, A Gilead Company
Phase 3
231
Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton
2022-09-22
Active, closed
The Euro-CRAFT Registry
NCT05805462Coronary Microvascular Disease
CoreAalst BV
Observational
671
Bath, Bristol, Essex, Glasgow, London, Oxford
2022-09-22
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066Follicular Lymphoma (FL)
Genmab
Phase 3
549
Plymouth, Glasgow, London, Oxford, Leeds, Birmingham, Colchester, Liverpool
2022-09-20
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 2
577
Belfast, Cambridge, Glasgow, High Wycombe, London, Oxford
2022-09-19
Active, closed
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
NCT05570058IPF, Fibrosis
Redx Pharma Ltd
Phase 2
48
Belfast, Birmingham, Cambridge, Edinburgh, London, Londonderry, Oxford
2022-09-08
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2
361
Preston, Glasgow, Birmingham, London, Manchester, Oxford, Southampton
2022-09-01
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals
Phase 4
347
London, Oxford
2022-08-30
Active, closed
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Biogen
Phase 2
416
London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol
2022-08-24
Active, closed
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
NCT05536973Neovascular Age-related Macular Degeneration
Adverum Biotechnologies, Inc.
Phase 2
69
London, Oxford
2022-08-23
By invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
NCT05374590Generalized Myasthenia Gravis, gMG
argenx
Phase 2/3
12
London, Oxford
2022-08-18
Active, closed
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
NCT05494606Ulcerative Colitis
AbbVie
Observational
785
Exeter, Hull, Basingstoke, Bury, Kettering, Nottingham, Oxford, Belfast
2022-08-15
Recruiting
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
NCT05463263Lymphoma, B-Cell, Lymphoma, T-Cell
Step Pharma, SAS
Phase 1/2
180
Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton
2022-08-03
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Belfast, Birmingham, Cambridge, Glasgow, High Wycombe, London, Oxford, Wolverhampton
2022-07-22
Recruiting
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
NCT04165486Multiple System Atrophy
Ionis Pharmaceuticals, Inc.
Phase 1
40
London, Oxford, Salford, Southampton
2022-07-21
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Truro, London, Oxford, Manchester
2022-07-21
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Bristol, Glasgow, London, Middlesbrough, Oxford, Sheffield, Southampton
2022-07-20
Active, closed
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
Biohaven Pharmaceuticals, Inc.
Phase 3
269
Glasgow, Oxford
2022-07-06
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
Celgene
Phase 3
939
Nottingham, Belfast Northern Ireland, Birmingham, Canterbury Kent, Lancashire Blackpool, London, Oxford, Portsmouth
2022-06-23
Active, closed
Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)
NCT05062291Venous Stenosis, Venous Occlusion
Merit Medical Systems, Inc.
Observational
500
Belfast, Birmingham, London, Oxford, Reading
2022-06-23
Recruiting
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
AC Immune SA
Phase 1/2
304
Cambridge, Liverpool, London, Oxford, Warrington
2022-06-21
Active, closed
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
ADC Therapeutics S.A.
Phase 1
154
London, Oxford
2022-06-17
Recruiting
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
NCT05429632Adult Acute Myeloid Leukemia
Priothera SAS
Phase 3
366
Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford
2022-06-16
Active, closed
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
NCT05115110Spinal Muscular Atrophy (SMA)
Hoffmann-La Roche
Phase 2/3
97
Birmingham, Oxford
2022-06-02
Active, closed
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
NCT05155254Metastatic Melanoma, Unresectable Melanoma
IO Biotech
Phase 3
407
London, Manchester, Oxford
2022-05-17
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
Nurix Therapeutics, Inc.
Phase 1
572
Manchester, Glasgow, Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2022-04-13
Active, closed
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05210790Polycythemia Vera
Protagonist Therapeutics, Inc.
Phase 3
293
Uxbridge, Barnet, Boston, Harrow, London, Oxford
2022-04-01
Recruiting
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553Active Juvenile Psoriatic Arthritis
Amgen
Phase 3
60
Birmingham, Liverpool, Nottingham, Oxford
2022-03-17
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Hoffmann-La Roche
Phase 1
332
Manchester, Oxford
2022-03-07
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Recruiting
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
NCT05027906Prevention of Rejection in Kidney Transplant
Eledon Pharmaceuticals
Phase 1/2
48
Liverpool, Oxford
2022-02-18
Active, closed
Clinical Impact of the IBox As an Early Intervention TooL
NCT05112315Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications
Predict4Health
Not applicable
507
Birmingham, Leeds, London, Oxford
2022-02-18
By invitation
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05076617Stereotypical Prolonged Seizures
UCB Biopharma SRL
Phase 3
300
Birmingham, Glasgow, London, Oxford, Salford
2022-02-03
Active, closed
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
UCB Biopharma SRL
Phase 3
113
Liverpool, Oxford
2022-02-02
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
AbbVie
Phase 3
735
Aylesbury, London, Gloucester, Southampton, Oxford, Leeds, Bradford, Bristol
2022-01-13
Active, closed
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
NCT05127226Angelman Syndrome
Ionis Pharmaceuticals, Inc.
Phase 1/2
71
Oxford
2021-12-22
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287Asthma
Sanofi
Phase 4
1,339
Cambridge, Oxford, Bradford, Liverpool, Newcastle upon Tyne, Wakefield
2021-12-16
Recruiting
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904Stereotypical Prolonged Seizures
UCB Biopharma SRL
Phase 3
350
Birmingham, Cardiff, Glasgow, London, Oxford, Salford
2021-12-07
Recruiting
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT04910685Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2/3
534
Cardiff, London, Oxford, Plymouth
2021-11-30
Recruiting
Research and Development of Novel Quantitative Magnetic Resonance Imaging (MRI) Techniques in a Single Scan for Multiple Organ Application
NCT05110248Multiple
Perspectum
Observational
600
Oxford
2021-11-15
Recruiting
Medical Affairs Pharmaceutical Physician Work-related Quality of Life (MAPPWrQoL) Instrument Development and Patient Registry (MAPPWrQoLReg)
NCT05123846Quality of Life
Medialis Ltd.
Observational
180
Oxford
2021-11-03
Recruiting
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
NCT05104515Prostate Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
Oxford Vacmedix UK Ltd.
Phase 1
36
London, Manchester, Oxford
2021-11-01
Recruiting
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
NCT04833894Generalized Myasthenia Gravis
argenx
Phase 2/3
12
London, Manchester, Oxford
2021-10-26
Active, closed
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
1,899
Oxford
2021-10-20
Active, closed
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
587
Blackpool, Dundee, London, Oxford, Plymouth, Sutton
2021-10-14
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 3
405
London, Nottingham, Oxford
2021-10-06
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
Pfizer
Phase 3
893
Bournemouth, Oxford, Cardiff, Bristol, Canterbury, Manchester
2021-10-04
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
Nurix Therapeutics, Inc.
Phase 1
345
Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford
2021-09-29
Active, closed
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075Conventional Chondrosarcoma
Inhibrx Biosciences, Inc
Phase 2
206
London, Manchester, Oxford
2021-09-23
Active, closed
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT05050097Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
166
London, Manchester, Oxford, Surrey
2021-09-22
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
600
Birmingham, Leeds, Leicester, London, Oxford, Plymouth
2021-09-20
Recruiting
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
NCT04528082Behçet Disease
Amgen
Phase 3
60
Birmingham, Liverpool, Oxford
2021-09-09
Active, closed
Contrast-Free Magnetic Resonance Imaging for Breast Disease
NCT05006196Breast Cancer, Breast Diseases
Perspectum
Observational
1,030
Oxford
2021-07-06
Active, closed
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
NCT04703192Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Daiichi Sankyo
Phase 2
155
London, Nottingham, Oxford
2021-06-03
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Eli Lilly and Company
Phase 3
150
London, Oxford, Sheffield
2021-05-26
By invitation
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)
Cytokinetics
Phase 2/3
900
Birmingham, Dundee, Glasgow, Liverpool, London, Oxford
2021-05-06
Active, closed
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331Parkinsons Disease
Hoffmann-La Roche
Phase 2
586
Dundee, London, Newcastle, Oxford, Peterborough, Plymouth
2021-05-05
Active, closed
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896Unresectable Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
557
Birmingham, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2021-04-26
Active, closed
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT04527380Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
Eli Lilly and Company
Phase 3
101
Bristol, Liverpool, Nottingham, Oxford, Stoke-on-Trent, Sheffield
2021-04-13
Active, closed
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156Myelofibrosis
Geron Corporation
Phase 3
327
London, Oxford
2021-04-12
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals
Phase 3
430
Edinburgh, Cardiff, Boston, Cambridge, Liverpool, London, Oxford
2021-04-09
Active, closed
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255Lymphoma, Mantle-Cell
Loxo Oncology, Inc.
Phase 3
500
Aberdeen, Plymouth, Newmarket, Glasgow, Nottingham, Oxford, Windsor
2021-04-08
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Merck Sharp & Dohme LLC
Phase 2
490
Bristol, Nottingham, Windsor, London, Oxford, Newmarket, Sutton, Manchester
2021-04-05
Active, closed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
London, Oxford, Sutton
2021-03-18
Active, closed
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389Myelofibrosis
Karyopharm Therapeutics Inc
Phase 3
353
London, Oxford, Boston, Liverpool, Newcastle upon Tyne
2021-03-11
Active, closed
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Celgene
Phase 3
313
Nottingham, Birmingham, Boston, Oxford
2021-02-25
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
Incyte Corporation
Phase 1
140
Boston, Lincoln, Manchester, Oxford
2021-02-23
Active, closed
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
NCT04624659Sickle Cell Disease
Forma Therapeutics, Inc.
Phase 3
450
Leicester, London, Oxford, Sheffield
2021-01-29
Active, closed
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
NCT04735978Advanced Solid Tumor
Replimune, Inc.
Phase 1
123
Bebington, London, Oxford
2020-12-29
Active, closed
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421Neoplasms
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Rows per page Showing 201–300 of 365
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/oxford?page=3

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.